Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.

Urology - 1 Nov 2005

Kohno Shin-ichi, Luo Chenhong, Goshima Fumi, Nishiyama Yukihiro, Sata Tetsutaro, Ono Yoshinari

Abstract excerpt

OBJECTIVES: To investigate the antitumor effects of the oncolytic herpes simplex virus (HSV) type 1 mutant HF10 on human and murine bladder cancer cells (T24 and MBT-2) in vitro and in immunocompetent mouse models. METHODS: In vitro viral oncolytic activity and the replication ability of HF10 were measured in T24 and MBT-2 cells. To evaluate the therapeutic efficacy of HF10, disseminated peritoneal and bladder...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus 1, Human
Share to Mice
Share to Mice, Inbred C3H

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Oncolytic Virotherapy

Share to Tumor Cells, Cultured

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 16286150
DOI: 10.1016/j.urology.2005.05.041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.PMID 16286150Read ↗

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.Semantic proximity Read ↗

[Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].Semantic proximity Read ↗

Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.Semantic proximity Read ↗

[Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].Semantic proximity Read ↗

The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.Semantic proximity Read ↗

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.Semantic proximity Read ↗

Gene therapy for mice sarcoma with oncolytic herpes simplex virus-1 lacking the apoptosis-inhibiting gene, icp34.5.Semantic proximity Read ↗

p53 Mutation in bladder cancer patients in Japan and inhibition of growth by in vitro adenovirus-mediated wild-type p53 transduction in bladder cancer cells.Semantic proximity Read ↗

Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer.Semantic proximity Read ↗

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.Semantic proximity Read ↗

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.Semantic proximity Read ↗

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.